Workflow
平台经济产业
icon
Search documents
“十四五”期间我国企业净增近2000万户,市场监管总局最新发声
Group 1: Market Regulation Achievements - The National Market Regulation Administration has improved the regulatory system for enterprise-related fees, continuously reducing operational costs for businesses, resulting in a net increase of 19.99 million enterprises and 33.946 million individual businesses during the "14th Five-Year Plan" period [1][2] - The introduction of the "Fair Competition Review Regulations" has established rigid institutional constraints against issues like malicious competition in investment promotion and administrative monopolies, with 4,218 obstructive policies abolished and 239 administrative monopoly cases investigated [1][2] Group 2: Consumer Protection and Efficiency - A total of 89.028 million complaints were handled by market regulation departments, recovering economic losses of 21.71 billion yuan for consumers, while consumer associations processed 5.749 million complaints, recovering 5.78 billion yuan [2] - The time to open a restaurant has been reduced from 37 days to 15 days, and the number of documents required for business information changes has been streamlined from 23 to 6 [2] Group 3: Platform Economy Regulation - The market regulation authority is addressing potential risks in the platform economy, such as algorithm abuse and disorderly competition, by balancing innovation encouragement and regulatory development [3][4] - Significant actions have been taken against market irregularities, including the removal of 4.541 million illegal product listings and the investigation of 105,000 internet-related cases [4] Group 4: Pharmaceutical Industry Growth - The pharmaceutical industry in China ranks second globally, with 204 innovative drugs and 265 innovative medical devices approved during the "14th Five-Year Plan," and 50 innovative drugs approved in the first seven months of this year [5][6] - The National Medical Products Administration has implemented dynamic supervision covering the entire drug lifecycle, focusing on key areas such as online sales and clinical trial management, while conducting over 200,000 drug inspections annually [6]